Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief ...

Biogen’s tau antisense Biogen also reported preliminary data at CTAD from a phase 1b study of BIIB080, an antisense drug targeting tau, in 46 mild Alzheimer’s patients. There were ...

Under Dr. Geary's leadership, Ionis submitted over 50 investigational new drug applications to regulatory agencies and ...